CN109394736B - Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof - Google Patents
Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof Download PDFInfo
- Publication number
- CN109394736B CN109394736B CN201811426173.4A CN201811426173A CN109394736B CN 109394736 B CN109394736 B CN 109394736B CN 201811426173 A CN201811426173 A CN 201811426173A CN 109394736 B CN109394736 B CN 109394736B
- Authority
- CN
- China
- Prior art keywords
- layer
- chitosan
- drug
- pcl
- nanofiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002121 nanofiber Substances 0.000 title claims abstract description 178
- 239000003814 drug Substances 0.000 title claims abstract description 139
- 229940079593 drug Drugs 0.000 title claims abstract description 130
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 238000001338 self-assembly Methods 0.000 title abstract description 26
- 239000003937 drug carrier Substances 0.000 title abstract description 20
- 229920001661 Chitosan Polymers 0.000 claims abstract description 151
- 239000012528 membrane Substances 0.000 claims abstract description 70
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 47
- 239000000648 calcium alginate Substances 0.000 claims abstract description 47
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 47
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 47
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 86
- 235000010413 sodium alginate Nutrition 0.000 claims description 86
- 239000000661 sodium alginate Substances 0.000 claims description 86
- 229940005550 sodium alginate Drugs 0.000 claims description 86
- 239000000243 solution Substances 0.000 claims description 83
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 33
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 24
- 238000009987 spinning Methods 0.000 claims description 15
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 12
- 229960004889 salicylic acid Drugs 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 11
- 238000010041 electrostatic spinning Methods 0.000 claims description 10
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000005342 ion exchange Methods 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003042 antagnostic effect Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000002035 prolonged effect Effects 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 231
- 229920001610 polycaprolactone Polymers 0.000 description 133
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 8
- 239000011247 coating layer Substances 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 3
- -1 0.5 Chemical compound 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/07—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with halogens; with halogen acids or salts thereof; with oxides or oxyacids of halogens or salts thereof
- D06M11/11—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with halogens; with halogen acids or salts thereof; with oxides or oxyacids of halogens or salts thereof with halogen acids or salts thereof
- D06M11/155—Halides of elements of Groups 2 or 12 of the Periodic Table
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/03—Polysaccharides or derivatives thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/01—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with natural macromolecular compounds or derivatives thereof
- D06M15/03—Polysaccharides or derivatives thereof
- D06M15/13—Alginic acid or derivatives thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/16—Synthetic fibres, other than mineral fibres
- D06M2101/30—Synthetic polymers consisting of macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M2101/32—Polyesters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Textile Engineering (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a layer-by-layer self-assembly nanofiber drug carrier and a preparation method thereof, and a layer-by-layer self-assembly drug-loaded nanofiber and a preparation method thereof, and relates to the technical field of nanofibers, wherein the layer-by-layer self-assembly nanofiber drug carrier comprises a PCL nanofiber membrane, a chitosan layer and a calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane, and the outermost layer is the chitosan layer, so that the technical problem that the drug effect can only be maintained in a short time and cannot reach the treatment effect when a patient uses a drug is solved; according to the layer-by-layer assembled nanofiber drug carrier provided by the invention, the chitosan layer and the calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane for carrying drugs, so that the drug release rate is slowed down, the drug release time is prolonged, the toxic and side effects on the body of a patient and the antagonistic action on the body of the patient are reduced, the total medical cost is reduced, and the recovery process of the patient is accelerated.
Description
Technical Field
The invention relates to the technical field of nano fibers, in particular to a layer-by-layer self-assembly nano fiber drug carrier and a preparation method thereof, and a layer-by-layer self-assembly drug-loaded nano fiber and a preparation method thereof.
Background
With the progress of science and technology and the continuous improvement of the living standard of people, the health problem becomes the focus of attention of people increasingly. Thus, there is an increasing demand for drugs in the medical field. With the use of general drugs, the drug effect can be maintained only for a relatively short period of time, and the fluctuation of the drug concentration during this period is large, and sometimes the drug concentration exceeds the tolerable range of the patient, causing side effects to the patient. Sometimes, the dosage is lower than the effective dosage of the medicine, so that the medicine cannot achieve the required therapeutic effect.
Therefore, the technology in the field needs to develop a novel sustained-release drug to slow down the release rate of the drug through the sustained-release drug, prolong the effective acting time of the drug, reduce the toxic and side effects on the body of the patient, reduce the antagonistic action on the body of the patient, and reduce the total medical cost.
Disclosure of Invention
One of the purposes of the invention is to provide a layer-by-layer self-assembly nanofiber drug carrier with a drug slow-release function, so as to solve the technical problem that the drug effect can only be maintained in a short time and the treatment effect cannot be achieved when a patient uses the drug.
The layer-by-layer self-assembly nanofiber drug carrier provided by the invention comprises a PCL nanofiber membrane, wherein a chitosan layer and a calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane, and the outermost layer is the chitosan layer.
The invention also aims to provide a preparation method of the layer-by-layer self-assembled nanofiber drug carrier, which comprises the following steps:
(a) soaking the PCL nanofiber membrane in a buffer solution to remove protons;
(b) immersing the PCL nanofiber membrane without protons into a chitosan solution to enable chitosan to be assembled on the outer surface of the PCL nanofiber membrane, and obtaining PCL nanofiber with the outer surface coated with a chitosan layer;
(c) immersing the PCL nanofiber with the outer surface coated with the chitosan layer into a sodium alginate solution to enable the sodium alginate layer to be assembled on the chitosan layer, and obtaining the PCL nanofiber with the outer surface sequentially coated with the chitosan layer and the sodium alginate layer;
(d) immersing the PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution to enable the chitosan layer to be assembled on the sodium alginate layer, so as to obtain the PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(e) and (3) immersing the PCL nanofiber with the outer surface coated with a chitosan layer, a sodium alginate layer and a chitosan layer in sequence into a calcium chloride solution, so that the sodium alginate layer and the calcium chloride are subjected to ion exchange reaction to generate a calcium alginate layer, and drying to obtain the layer-by-layer self-assembled nanofiber drug carrier.
Further, in the step (e), after the calcium alginate layer is generated, the calcium alginate layer is continuously immersed into the sodium alginate solution, the chitosan solution and the calcium chloride solution in sequence, repeated for a plurality of times, and then dried.
Further, in the chitosan solution, the mass volume concentration of chitosan is 0.5-1.5g/L, preferably 1 g/L;
and/or in the sodium alginate solution, the mass volume concentration of the sodium alginate is 0.5-1.5g/L, preferably 1 g/L;
and/or the mass concentration of calcium chloride in the calcium chloride solution is 3-5%, preferably 4%.
Further, the PCL nanofiber membrane is prepared through electrostatic spinning;
preferably, the preparation method of the PCL nanofiber membrane comprises the following steps: firstly, dissolving PCL in a solvent to obtain a PCL spinning solution, and then carrying out electrostatic spinning on the PCL spinning solution to obtain a PCL nanofiber membrane;
preferably, the mass concentration of the PCL in the PCL spinning solution is 10-15%, preferably 12%;
preferably, the solvent of the PCL spinning solution is a mixed solution of dichloromethane and N, N-dimethylformamide;
further preferably, the mass ratio of dichloromethane to N, N-dimethylformamide in the solvent is (4-8):1, preferably 6: 1.
Further, in step (a), the pH value of the buffer solution is 7.5-8.5, preferably 8;
and/or, in step (e), the drying is freeze-drying.
The invention also aims to provide a layer-by-layer self-assembly drug-loaded nanofiber, which comprises a drug-loaded PCL nanofiber membrane, wherein a chitosan layer and a calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the drug-loaded PCL nanofiber membrane, and the outermost layer is the chitosan layer.
The fourth purpose of the invention is to provide a preparation method of the layer-by-layer self-assembly drug-loaded nanofiber, which comprises the following steps:
(A) soaking the PCL nanofiber membrane carrying the medicine in a buffer solution to remove protons;
(B) immersing the drug-loaded PCL nanofiber membrane without protons into a chitosan solution to enable chitosan to be assembled on the outer surface of the drug-loaded PCL nanofiber membrane, and obtaining the drug-loaded PCL nanofiber with a chitosan layer coated on the outer surface;
(C) soaking the medicine-carrying PCL nanofiber with the chitosan layer coated on the outer surface into a sodium alginate solution to enable the sodium alginate layer to be assembled on the chitosan layer, and obtaining the medicine-carrying PCL nanofiber with the chitosan layer and the sodium alginate layer sequentially coated on the outer surface;
(D) soaking the drug-loaded PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution to enable the chitosan layer to be assembled on the sodium alginate layer, so as to obtain the drug-loaded PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(E) immersing the drug-loaded PCL nanofiber with the outer surface coated with a chitosan layer, a sodium alginate layer and a chitosan layer in sequence into a calcium chloride solution to enable the sodium alginate layer and the calcium chloride to generate an ion exchange reaction to generate a calcium alginate layer, and drying to obtain the layer-by-layer self-assembled drug-loaded nanofiber;
preferably, in the step (E), after the calcium alginate layer is generated, the calcium alginate layer is continuously immersed in the sodium alginate solution, the chitosan solution and the calcium chloride solution in sequence, repeated for a plurality of times, and then dried.
Further, in the chitosan solution, the mass volume concentration of chitosan is 0.5-1.5g/L, preferably 1 g/L;
and/or in the sodium alginate solution, the mass volume concentration of the sodium alginate is 0.5-1.5g/L, preferably 1 g/L;
and/or the mass concentration of calcium chloride in the calcium chloride solution is 3-5%, preferably 4%.
Further, the drug-loaded PCL nanofiber membrane is prepared through electrostatic spinning;
preferably, the preparation method of the drug-loaded PCL nanofiber membrane comprises the following steps:
preparing a drug and PCL into a drug solution and a PCL solution respectively, mixing the drug solution and the PCL solution to obtain a drug-loaded spinning solution, and performing electrostatic spinning on the drug-loaded spinning solution to obtain a drug-loaded PCL nanofiber membrane;
preferably, the drug is a hydrophobic drug, preferably salicylic acid.
According to the layer-by-layer assembled nanofiber drug carrier provided by the invention, the chitosan layer and the calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane for carrying drugs, so that the drug release rate is slowed down, the drug release time is prolonged, the toxic and side effects on the body of a patient and the antagonistic action on the body of the patient are reduced, the total medical cost is reduced, and the recovery process of the patient is accelerated.
According to the layer-by-layer assembled drug-loaded nanofiber provided by the invention, the drug is loaded through the PCL nanofiber membrane, and the chitosan layer and the calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane loaded with the drug, so that the drug release rate is slowed down, the drug release time is prolonged, the toxic and side effects on the body of a patient and the antagonistic action on the body of the patient are reduced, the total medical cost is reduced, and the recovery process of the patient is accelerated.
Drawings
Fig. 1 is a flow chart of a process for preparing layer-by-layer self-assembled drug-loaded nanofibers according to embodiment 1 of the present invention;
fig. 2 is a drug release curve of layer-by-layer self-assembled drug-loaded nanofibers provided in examples 6 to 7 of the present invention;
fig. 3 is a drug release curve of the drug-loaded PCL nanofiber membrane provided in comparative example 1 of the present invention.
Detailed Description
The technical solutions of the present invention are described clearly and completely below, and it is obvious that the described embodiments are some, not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
According to one aspect of the invention, the invention provides a layer-by-layer self-assembly nanofiber drug carrier, which comprises a PCL nanofiber membrane, wherein a chitosan layer and a calcium alginate layer are sequentially arranged on the outer surface of the PCL nanofiber membrane at intervals, and the outermost layer is the chitosan layer.
In the present invention, PCL means polycaprolactone.
According to the layer-by-layer assembled nanofiber drug carrier provided by the invention, the chitosan layer and the calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane for carrying drugs, so that the drug release rate is slowed down, the drug release time is prolonged, the toxic and side effects on the body of a patient and the antagonistic action on the body of the patient are reduced, the total medical cost is reduced, and the recovery process of the patient is accelerated.
In the invention, the outer surface of the PCL nanofiber membrane is coated with a chitosan layer, a calcium alginate layer and a chitosan layer which are sequentially stacked, wherein the chitosan layer and the calcium alginate layer are arranged at intervals, and can be arranged at intervals once or for multiple times.
According to a second aspect of the present invention, the present invention provides a method for preparing a layer-by-layer self-assembled nanofiber drug carrier, comprising the following steps:
(a) soaking the PCL nanofiber membrane in a buffer solution to remove protons;
(b) immersing the PCL nanofiber membrane without protons into a chitosan solution to enable chitosan to be assembled on the outer surface of the PCL nanofiber membrane, and obtaining PCL nanofiber with the outer surface coated with a chitosan layer;
(c) immersing the PCL nanofiber with the outer surface coated with the chitosan layer into a sodium alginate solution to enable the sodium alginate layer to be assembled on the chitosan layer, and obtaining the PCL nanofiber with the outer surface sequentially coated with the chitosan layer and the sodium alginate layer;
(d) immersing the PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution to enable the chitosan layer to be assembled on the sodium alginate layer, so as to obtain the PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(e) and (3) immersing the PCL nanofiber with the outer surface coated with a chitosan layer, a sodium alginate layer and a chitosan layer in sequence into a calcium chloride solution, so that the sodium alginate layer and the calcium chloride are subjected to ion exchange reaction to generate a calcium alginate layer, and drying to obtain the layer-by-layer self-assembled nanofiber drug carrier.
In the invention, in the step (a), the PCL nanofiber membrane is made to have certain electronegativity by removing protons, so that the PCL nanofiber membrane and chitosan can be subjected to electrostatic adsorption.
In the step (b), the PCL nanofiber membrane with the protons removed adsorbs chitosan on the PCL nanofiber membrane through electrostatic action, and then is washed by deionized water to obtain the PCL nanofiber membrane coated with the chitosan layer.
In the step (c), the PCL nanofiber membrane coated with the chitosan layer is immersed in a sodium alginate solution, a sodium alginate layer is adsorbed outside the chitosan layer through electrostatic adsorption, and then washing is carried out through deionized water, so that the PCL nanofiber with the outer surface sequentially coated with the chitosan layer and the sodium alginate layer is obtained.
In the step (d), the PCL nanofiber with the outer surface sequentially coated with the chitosan layer and the sodium alginate layer is immersed in a chitosan solution, so that chitosan is adsorbed outside the sodium alginate layer under the action of static electricity, and then the PCL nanofiber sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer is obtained through washing with deionized water.
In the step (d), the PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer is immersed in a calcium chloride solution, so that the sodium alginate in the sodium alginate layer and the calcium chloride are subjected to ion exchange reaction to generate the calcium alginate layer, and then the calcium alginate layer is washed by deionized water to obtain the PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the calcium alginate layer and the chitosan layer, namely the PCL nanofiber drug carrier is self-assembled layer by layer.
In a preferred embodiment of the present invention, in order to obtain a nanofiber drug carrier with an outer surface coated with a plurality of chitosan layers and calcium alginate layers, in step (e), after the calcium alginate layer is generated, the calcium alginate layer is sequentially added into a sodium alginate solution, a chitosan solution and a calcium chloride solution, and the above steps are repeated for a plurality of times, so as to obtain a layer-by-layer self-assembled nanofiber drug carrier with an outer surface coated with chitosan layers and calcium alginate layers which are sequentially stacked, and an outermost layer is a chitosan layer.
In a preferred embodiment of the invention, the chitosan solution has a mass volume concentration of chitosan of 0.5-1.5 g/L.
In a preferred embodiment of the invention, the chitosan solution has a typical, but not limiting, mass to volume concentration of chitosan, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5 g/L.
By controlling the mass volume concentration of the chitosan solution, the chitosan can be adsorbed on the surface of the PCL nanofiber membrane to form a chitosan layer.
In a preferred embodiment of the invention, the sodium alginate solution has a mass volume concentration of 0.5-1.5g/L sodium alginate.
In a preferred embodiment of the invention, the sodium alginate solution has a typical, but not limiting, mass volume concentration of sodium alginate, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5 g/L.
By controlling the mass volume concentration of the sodium alginate solution, the sodium alginate can be adsorbed on the surface of the chitosan layer to form a sodium alginate layer.
In a preferred embodiment of the invention, the calcium chloride solution has a mass concentration of 3 to 5%.
In a preferred embodiment of the invention, the calcium chloride solution has a typical but non-limiting mass concentration of, for example, 3%, 3.5%, 4%, 4.5% or 5%.
The mass concentration of the calcium chloride solution is controlled so that the calcium chloride solution can generate calcium ion exchange reaction with sodium alginate in the sodium alginate layer to form calcium alginate.
In a preferred embodiment of the invention, the PCL nanofibrous membrane is prepared by electrospinning.
In a further preferred embodiment of the invention, the method for preparing the PCL nanofiber membrane comprises the following steps: firstly, dissolving PCL in a solvent to obtain a PCL spinning solution, and then carrying out electrostatic spinning on the PCL spinning solution to obtain the PCL nano-fiber membrane.
In a preferred embodiment of the invention, the PCL dope has a mass concentration of PCL of 10 to 15%.
In a preferred embodiment of the invention, the PCL dope is typically, but not limited to, 10%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5% or 15% by mass of PCL.
The PCL spinning solution with better spinnability can be obtained by controlling the mass concentration of the PCL spinning solution to be 10-15%.
In a preferred embodiment of the present invention, the solvent of the PCL dope is a mixture of dichloromethane and N, N-dimethylformamide.
The mixed solution of dichloromethane and N, N-dimethylformamide is selected as a solvent, so that the solubility of the PCL is improved, and the PCL nanofiber membrane with more excellent performance is prepared.
In a further preferred embodiment of the present invention, the mass ratio of dichloromethane and N, N-dimethylformamide in the solvent is (4-8):1, preferably 6: 1.
In a preferred embodiment of the invention, typical but non-limiting masses of dichloromethane and N, N-dimethylformamide in the solvent are, for example, 4:1, 5:1, 6:1, 7:1 or 8: 1.
In a preferred embodiment of the invention, in step (a), the buffer has a pH of 7.5 to 8.5.
In a preferred embodiment of the invention, in step (a), the buffer has a typical but non-limiting pH value of, for example, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4 or 8.5.
The pH value of the buffer solution is controlled so that the deionization rate of the PCL fiber membrane can be accelerated.
In a preferred embodiment of the present invention, in step (e), the drying is freeze-drying.
According to a third aspect of the invention, the invention provides a layer-by-layer self-assembly drug-loaded nanofiber, which comprises a drug-loaded PCL nanofiber membrane, wherein a chitosan layer and a calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the drug-loaded PCL nanofiber membrane, and the outermost layer is the chitosan layer.
According to the layer-by-layer assembled drug-loaded nanofiber provided by the invention, the drug is loaded through the PCL nanofiber membrane, and the chitosan layer and the calcium alginate layer which are sequentially arranged at intervals are assembled on the outer surface of the PCL nanofiber membrane loaded with the drug, so that the drug release rate is slowed down, the drug release time is prolonged, the toxic and side effects on the body of a patient and the antagonistic action on the body of the patient are reduced, the total medical cost is reduced, and the recovery process of the patient is accelerated.
According to a fourth aspect of the invention, the invention provides a preparation method of a layer-by-layer self-assembled drug-loaded nanofiber, which comprises the following steps:
(A) soaking the PCL nanofiber membrane carrying the medicine in a buffer solution to remove protons;
(B) immersing the drug-loaded PCL nanofiber membrane without protons into a chitosan solution to enable chitosan to be assembled on the outer surface of the drug-loaded PCL nanofiber membrane, and obtaining the drug-loaded PCL nanofiber with a chitosan layer coated on the outer surface;
(C) soaking the medicine-carrying PCL nanofiber with the chitosan layer coated on the outer surface into a sodium alginate solution to enable the sodium alginate layer to be assembled on the chitosan layer, and obtaining the medicine-carrying PCL nanofiber with the chitosan layer and the sodium alginate layer sequentially coated on the outer surface;
(D) soaking the drug-loaded PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution to enable the chitosan layer to be assembled on the sodium alginate layer, so as to obtain the drug-loaded PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(E) the medicine-carrying PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer is immersed in a calcium chloride solution, so that the sodium alginate layer and calcium chloride are subjected to ion exchange reaction to generate the calcium alginate layer, and the calcium alginate layer is dried to obtain the layer-by-layer self-assembled medicine-carrying nanofiber.
The preparation method of the layer-by-layer self-assembly drug-loaded nanofiber provided by the invention is different from the layer-by-layer self-assembly nanofiber drug carrier in that drugs are added into a PCL spinning solution, a drug-loaded PCL nanofiber membrane is obtained through electrostatic spinning, and the rest steps of sequentially assembling a chitosan layer, a calcium alginate layer and a chitosan layer on the surface of the drug-loaded PCL nanofiber membrane are the same as the steps of the nanofiber drug carrier, and are not repeated herein.
In a preferred embodiment of the present invention, in step (E), after the calcium alginate layer is generated, the solution continues to enter the sodium alginate solution, the chitosan solution and the calcium chloride solution in sequence, and the process is repeated for a plurality of times, so that the outer surface of the drug-loaded PCL nanofiber membrane is coated with a plurality of chitosan layers and calcium alginate layers which are arranged in sequence, and the outermost layer is the chitosan layer.
In a preferred embodiment of the invention, the chitosan solution has a typical, but not limiting, mass-to-volume concentration of chitosan, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5 g/L.
By controlling the mass volume concentration of the chitosan solution, the chitosan can be adsorbed on the surface of the PCL nanofiber membrane to form a chitosan layer.
In a preferred embodiment of the invention, the sodium alginate solution has a mass volume concentration of 0.5-1.5g/L sodium alginate.
In a preferred embodiment of the invention, the sodium alginate solution has a typical, but not limiting, mass volume concentration of sodium alginate, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5 g/L.
By controlling the mass volume concentration of the sodium alginate solution, the sodium alginate can be adsorbed on the surface of the chitosan layer to form a sodium alginate layer.
In a preferred embodiment of the invention, the calcium chloride solution has a mass concentration of 3 to 5%.
In a preferred embodiment of the invention, the calcium chloride solution has a typical but non-limiting mass concentration of, for example, 3%, 3.5%, 4%, 4.5% or 5%.
The mass concentration of the calcium chloride solution is controlled so that the calcium chloride solution can generate calcium ion exchange reaction with sodium alginate in the sodium alginate layer to form calcium alginate.
In a preferred embodiment of the invention, the preparation method of the drug-loaded PCL nanofiber membrane comprises the following steps:
firstly, preparing a drug and PCL into a drug solution and a PCL solution respectively, then mixing the drug solution and the PCL solution to obtain a drug-loaded spinning solution, and carrying out electrostatic spinning on the drug-loaded spinning solution to obtain the drug-loaded PCL nanofiber membrane.
The drug-loaded PCL nanofiber membrane provided by the invention is prepared by an electrostatic spinning method, the process is simple, and the moldability of the drug-loaded PCL nanofiber membrane is good.
In a preferred embodiment of the invention, the drug is a hydrophobic drug, including but not limited to salicylic acid.
The technical solution provided by the present invention is further described below with reference to examples and comparative examples.
Example 1
The embodiment provides a layer-by-layer self-assembled drug-loaded nanofiber, and the preparation process is shown in fig. 1, and as can be seen from fig. 1, the method specifically comprises the following steps:
(1) preparing a mixed solution of PCL and Salicylic Acid (SA), wherein the mass concentration of the PCL is 12%, and the mass concentration of the SA is 1%;
(2) carrying out electrostatic spinning on the mixed solution of PCL and SA to obtain a medicine-carrying PCL nanofiber membrane;
(3) placing the PCL nanofiber membrane with drug loading in a buffer solution with the pH value of 8, and removing protons;
(4) immersing the drug-loaded PCL nanofiber membrane without protons into a chitosan solution with the volume concentration of 1g/L to ensure that chitosan is assembled on the outer surface of the drug-loaded PCL nanofiber membrane to obtain the drug-loaded PCL nanofiber with the outer surface coated with a chitosan layer;
(5) immersing the PCL drug-loaded nanofiber with the chitosan layer coated on the outer surface into a sodium alginate solution with the volume concentration of 1g/L to enable the sodium alginate layer to be assembled on the chitosan layer, so as to obtain the drug-loaded PCL nanofiber with the chitosan layer and the sodium alginate layer sequentially coated on the outer surface;
(6) immersing the drug-loaded PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution with the mass volume concentration of 1g/L, so that the chitosan layer is assembled on the sodium alginate layer, and obtaining the drug-loaded PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(7) the medicine-carrying PCL nanofiber with the outer surface coated with the chitosan layer, the sodium alginate layer and the chitosan layer in sequence is immersed in a calcium chloride solution, so that the sodium alginate layer and calcium chloride are subjected to ion exchange reaction to generate the calcium alginate layer, and freeze-drying is carried out to obtain the layer self-assembly medicine-carrying nanofiber with the outer surface coated with the chitosan layer, the calcium alginate layer and the chitosan layer in a 3-layer structure in sequence.
Example 2
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that of embodiment 1 in that in step (1), the mass concentration of PCL is 10%.
Example 3
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that of embodiment 1 in that in step (1), the mass concentration of PCL is 15%.
Example 4
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that of embodiment 1 in that in step (1), the mass concentration of PCL is 5%.
Example 5
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that of embodiment 1 in that in step (1), the mass concentration of PCL is 30%.
Example 6
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that in the embodiment 1, in the step (7), after a calcium alginate layer is generated, the calcium alginate layer continues to enter a sodium alginate solution, a chitosan solution and a calcium chloride solution sequentially for 4 times, and the layer-by-layer self-assembly drug-loaded nanofiber which is sequentially coated with 11 layers of chitosan layers and calcium alginate layers is obtained.
Example 7
The embodiment provides a layer-by-layer self-assembly drug-loaded nanofiber, and the preparation method is different from that in the embodiment 1, in the step (7), after a calcium alginate layer is generated, the calcium alginate layer continues to enter a sodium alginate solution, a chitosan solution and a calcium chloride solution sequentially for 9 times, and the layer-by-layer self-assembly drug-loaded nanofiber which is sequentially coated with 21 layers of chitosan layers and calcium alginate layers is obtained.
Comparative example 1
This comparative example provides a drug-loaded PCL nanofiber membrane, and the preparation method thereof is the same as steps (1) and (2) in example 1, and details are not repeated here.
Test example 1
The nanofibers provided in examples 1-7 and comparative example 1 were observed by scanning electron microscopy, respectively, and the results show that the nanofibers provided in examples 1-3, 6-7 and comparative example 1 have smooth surfaces and good moldability, while the nanofibers provided in examples 4-5 have poor moldability, which indicates that when the drug-loaded PCL nanofibers are prepared, the drug-loaded PCL nanofibers with good moldability can be prepared when the mass concentration of PCL is 10-15%.
The average diameters of the drug-loaded nanofibers provided in examples 1 to 3, examples 6 to 7, and comparative example 1 were observed by a scanning electron microscope, and the results are shown in table 1.
TABLE 1 diameter data table of drug-loaded nanofibers
| Group of | Average diameter (nm) |
| Example 1 | 550 |
| Example 2 | 546 |
| Example 3 | 556 |
| Example 6 | 799 |
| Example 7 | 1284 |
| Comparative example 1 | 434 |
As can be seen from table 1, the diameters of the drug-loaded nanofibers provided in examples 1 to 3 and examples 6 to 7 are significantly higher than that of comparative example 1, which indicates that the drug-loaded nanofibers provided in examples 1 to 7 and examples 6 to 7 are successfully coated with a chitosan layer, a calcium alginate layer and a chitosan layer on the surface of the drug-loaded PCL nanofibers.
As can be seen from the comparison between examples 6-9 and examples 1-3, the larger the number of coating layers, the larger the diameter of the drug-loaded nanofiber, when the coating layer is 3 layers, the diameter of the drug-loaded nanofiber is between 500-850 nm, when the coating layer is 11 layers, the diameter of the drug-loaded nanofiber is between 700-850nm, and when the number of coating layers is 21 layers, the diameter of the drug-loaded nanofiber is between 1100-1400 nm.
Test example 2
The drug-loaded nanofibers provided in examples 6-7 and comparative example 1 were monitored for 72 hours salicylic acid release and the results are shown in table 2.
Table 2 drug-loaded nanofiber salicylic acid release performance data table
| Time (h) | Example 6 | Example 7 | Comparative example 1 |
| 0.25 | 0.003127 | 0.004697 | 0.11968 |
| 0.5 | 0.003543 | 0.00422 | 0.080891 |
| 1 | 0.005816 | 0.007171 | 0.04367 |
| 2 | 0.00541 | 0.007517 | 0.029301 |
| 4 | 0.007546 | 0.008235 | 0.042952 |
| 8 | 0.007746 | 0.007073 | 0.036652 |
| 24 | 0.00808 | 0.007814 | 0.030636 |
| 48 | 0.009261 | 0.008982 | 0.04056 |
| 72 | 0.009567 | 0.01034 | 0.046104 |
According to the data fitting salicylic acid drug release curves, the drug release curves of examples 6-7 are shown in fig. 2, the drug release curve provided by comparative example 1 is shown in fig. 3, and as can be seen from fig. 2 and fig. 3, the drug release rate can be significantly reduced and the therapeutic effect of the drug can be improved by coating the chitosan layer, the calcium alginate layer and the chitosan layer on the surface of the drug-loaded PCL nanofiber membrane. However, the release rate of the drug is not obviously slowed down with the increase of the coating layers, particularly, the diameter of the drug-loaded nanofiber is increased with the increase of the coating layers, and the capability of the drug-loaded nanofiber for penetrating cell membranes is reduced, so that when the coating layers are 10-15 layers, the comprehensive performance of the drug-loaded nanofiber is better.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (2)
1. A preparation method of layer-by-layer self-assembled drug-loaded nanofiber is characterized by comprising the following steps:
(A) soaking the PCL nanofiber membrane carrying the medicine in a buffer solution to remove protons;
(B) immersing the proton-removed medicine-carrying PCL nanofiber membrane into a chitosan solution with the mass volume concentration of 1g/L, so that chitosan is assembled on the outer surface of the medicine-carrying PCL nanofiber membrane, and obtaining the medicine-carrying PCL nanofiber with the outer surface coated with a chitosan layer;
(C) soaking the medicine-carrying PCL nanofiber with the chitosan layer coated on the outer surface into a sodium alginate solution with the mass volume concentration of 1g/L to enable the sodium alginate layer to be assembled on the chitosan layer, and obtaining the medicine-carrying PCL nanofiber with the chitosan layer and the sodium alginate layer sequentially coated on the outer surface;
(D) soaking the drug-loaded PCL nanofiber with the outer surface sequentially coated with a chitosan layer and a sodium alginate layer into a chitosan solution to enable the chitosan layer to be assembled on the sodium alginate layer, so as to obtain the drug-loaded PCL nanofiber with the outer surface sequentially coated with the chitosan layer, the sodium alginate layer and the chitosan layer;
(E) immersing the drug-loaded PCL nanofiber with the outer surface coated with a chitosan layer, a sodium alginate layer and a chitosan layer in sequence into a calcium chloride solution with the mass concentration of 4% to enable the sodium alginate layer and the calcium chloride to generate an ion exchange reaction to generate a calcium alginate layer, and drying to obtain the layer-by-layer self-assembled drug-loaded nanofiber;
the preparation method of the medicine-carrying PCL nanofiber membrane comprises the following steps:
firstly, preparing salicylic acid and PCL into salicylic acid solution and PCL solution respectively, then mixing the salicylic acid solution and the PCL solution to obtain medicine-carrying spinning solution, and carrying out electrostatic spinning on the medicine-carrying spinning solution to obtain a medicine-carrying PCL nanofiber membrane;
layer upon layer self-assembling medicine carrying nanofiber includes medicine carrying PCL nanofiber membrane, the surface equipment of medicine carrying PCL nanofiber membrane has shell polysaccharide layer and the calcium alginate layer that sets up in proper order at an interval, and outmost being shell polysaccharide layer.
2. The method according to claim 1, wherein in the step (E), after the calcium alginate layer is formed, the calcium alginate layer is sequentially immersed in the sodium alginate solution, the chitosan solution and the calcium chloride solution, and is repeatedly dried.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811426173.4A CN109394736B (en) | 2018-11-27 | 2018-11-27 | Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811426173.4A CN109394736B (en) | 2018-11-27 | 2018-11-27 | Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109394736A CN109394736A (en) | 2019-03-01 |
| CN109394736B true CN109394736B (en) | 2022-04-12 |
Family
ID=65455757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811426173.4A Active CN109394736B (en) | 2018-11-27 | 2018-11-27 | Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109394736B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110917119A (en) * | 2019-11-18 | 2020-03-27 | 南通大学 | Sodium alginate drug-loaded fiber with skin-core structure and preparation method thereof |
| CN113244438B (en) * | 2021-04-29 | 2022-05-17 | 五邑大学 | Preparation method of three-dimensional functional medical dressing for diabetic foot ulcer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107261142A (en) * | 2017-06-05 | 2017-10-20 | 东华大学 | It is a kind of for porous filamentous nanocarbon base load medicine photothermal reagent of oncotherapy and preparation method thereof |
-
2018
- 2018-11-27 CN CN201811426173.4A patent/CN109394736B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107261142A (en) * | 2017-06-05 | 2017-10-20 | 东华大学 | It is a kind of for porous filamentous nanocarbon base load medicine photothermal reagent of oncotherapy and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Polysaccharide-Coated PCL Nanofibers for Wound Dressing Applications;Croisier, Florence et al.;《ADVANCED HEALTHCARE MATERIALS》;20140929;第3卷(第12期);摘要，Scheme 1.，第2037-2038页Layer-by-layer Deposition on the Nanofi ber Surface，第2037页Electrospinning of the Poly(ε-caprolactone) Blend * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109394736A (en) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108273392B (en) | Method for modifying hollow braided tube and method for producing hollow fiber membrane | |
| CN109394736B (en) | Layer-by-layer self-assembly nanofiber drug carrier and preparation method thereof, layer-by-layer self-assembly drug-loaded nanofiber and preparation method thereof | |
| EP3288600B1 (en) | Antibacterial nanofibres | |
| Li et al. | Tunable biphasic drug release from ethyl cellulose nanofibers fabricated using a modified coaxial electrospinning process | |
| Repanas et al. | Dipyridamole embedded in Polycaprolactone fibers prepared by coaxial electrospinning as a novel drug delivery system | |
| KR20080005549A (en) | Textiles containing at least one layer of polymeric nanofibres and method of production of the layer of polymeric nanofibres from the polymer solution through electrostatic spinning | |
| CN110144124B (en) | Composite material of quaternized chitin and silk fibroin and preparation and application thereof | |
| CN109267240B (en) | Chitosan/calcium alginate needle-free electrostatic spinning nanofiber membrane for medical dressing and preparation method thereof | |
| CN108425238B (en) | Preparation method of antibacterial graphene non-woven fabric with low resistance and high filtering efficiency for mask | |
| Barani | Antibacterial continuous nanofibrous hybrid yarn through in situ synthesis of silver nanoparticles: preparation and characterization | |
| CN102671235A (en) | High-orientation nanofiber nerve conduit and preparation method thereof | |
| Liu et al. | A bimodal protein fabric enabled via in situ diffusion for high-performance air filtration | |
| KR101641123B1 (en) | Flexible nanostructure photocatalyst of TiO2 nanoparticles-immobilized PVDF nanofabric and method for fabricating the same | |
| JP2021501837A (en) | Methods and systems for producing poly (glycerol sebacate) / alginate continuous fibers, and yarns containing continuous poly (glycerol sevacate) fibers. | |
| Park et al. | Fabrication and characterization of antimicrobial ethyl cellulose nanofibers using electrospinning techniques | |
| CN1837435B (en) | Composite nano-grade silk fiber product and method for preparing the same | |
| Kang et al. | Silver nanoparticles incorporated electrospun silk fibers | |
| US20160137802A1 (en) | Multiscale porous polymer films | |
| CN1874799A (en) | Medical device with electrospun nanofibers | |
| CN109338490B (en) | Preparation method of hollow multilayer structure fiber, obtained fiber and application thereof | |
| KR101111226B1 (en) | Nanofiber nonwoven fabric having chitosan layer and manufacturing method thereof | |
| CN113445155B (en) | Chitosan-based nanofiber and preparation method thereof | |
| KR20210053694A (en) | Polyaniline-polymer nanofiber composite and preparation method thereof | |
| Zheng et al. | Preparation of nanofiber core-spun yarn based on cellulose nanowhiskers/quaternary ammonium salts nanocomposites for efficient and durable antibacterial textiles | |
| CN111996677A (en) | Antibacterial MoS2Preparation method of PLGA nanofiber membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240117 Address after: Room 801, 85 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Yami Technology (Guangzhou) Co.,Ltd. Address before: 529000 No. 22 Dongcheng village, Guangdong City, Jiangmen Province Patentee before: WUYI University |